# Do GLP-1 Drugs Help Atrial Fibrillation? The Evidence Disagrees With Itself Do GLP-1 drugs help atrial fibrillation? Two TriNetX cohorts disagree on recurrence after ablation, and a 2.17-million-patient comparison found no clear benefit. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Atrial Fibrillation? The Evidence Disagrees With Itself One ablation cohort found a hazard ratio of 0.82 for recurrence. Another found 1.04. A larger comparison found no advantage over a near-neutral drug at all. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Atrial fibrillation recurrence after ablation · 1.0 · 3,350 pairs, 2 years · 0.82 · 1,625 pairs, 1 year · 1.04 · Same research network. Different cohorts, different answer. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). No clear answer yet, and the numbers explain why nobody can give one. Two analyses of the same research database asked whether a GLP-1 drug keeps atrial fibrillation from returning after catheter ablation. They landed on opposite conclusions: one found a hazard ratio of 0.82, the other found 1.04. A larger comparison, of 2,171,267 patients, found GLP-1 drugs no better than a near-neutral standard drug at preventing atrial fibrillation from developing in the first place, while a different drug class beat both — the full writeup is [here](https://thisglp.com/research/atrial-fibrillation-the-other-drug-won)[\[3\]](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation#ref-3). Whatever a seller's landing page claims about heart rhythm, this is the record it would be drawing from. ## Key takeaways - A 2026 analysis of 3,350 matched pairs found GLP-1 use before ablation cut atrial fibrillation recurrence, hazard ratio 0.82 (95% CI 0.76-0.88). - A 2024 analysis of 1,625 matched pairs found no benefit on a similar composite endpoint, hazard ratio 1.04 (95% CI 0.92-1.19). - Both used the same TriNetX research network; the cohorts differed in BMI criteria, follow-up length and outcome definition. - A separate network meta-analysis of 2,171,267 patients found GLP-1 drugs no different from DPP-4 inhibitors on new-onset atrial fibrillation (RR 0.93), while SGLT-2 inhibitors beat both. - For people who already have atrial fibrillation, no drug class separated from the others on recurrence. Atrial fibrillation comes back in a substantial minority of the people who have it burned out by catheter ablation, and weight is one of the few things a patient can change that is known to matter. So the question of whether a GLP-1 drug lowers the recurrence rate is not academic: it is the kind of claim a seller could reasonably be tempted to put on a landing page. The evidence, as it stands, will not support one. The reason why is worth following, because it is the same reason so many claims about this drug class read as more settled than they are — a habit visible on most of the [seller pages ranked here](https://thisglp.com/best). ## Two studies, one research network, opposite conclusions A multicenter analysis published in 2026 drew obese adults without a diabetes requirement from the TriNetX network, matched 3,350 GLP-1 users to 3,350 nonusers across 82 clinical and demographic variables, and followed them a median of two years. Recurrence was 6.66% among users against 7.72% among nonusers, a hazard ratio of 0.82 (95% CI 0.76 to 0.88, P < 0.0001)[\[1\]](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation#ref-1). Progression to permanent atrial fibrillation was also lower at a hazard ratio of 0.77 (95% CI 0.63 to 0.93), as were all-cause mortality at 0.73 (95% CI 0.59 to 0.91) and heart-failure hospitalization at 0.80 (95% CI 0.71 to 0.90). An earlier analysis, published in 2024, used the same TriNetX network to ask a question that sounds identical. It matched 1,625 preablation GLP-1 users to 1,625 nonusers and followed a composite of cardioversion, a new antiarrhythmic drug, or a repeat ablation over twelve months after a three-month blanking period. The hazard ratio was 1.04 (95% CI 0.92 to 1.19, log-rank P = 0.51) [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation#ref-2), and stroke, hospitalization and mortality did not differ either. The authors concluded the evidence does not support a benefit and called for research that would settle it. ## What differs is who was counted, and for how long The two cohorts are not the same people asked the same question. The 2026 analysis required a body mass index above 30 and excluded nobody on the basis of diabetes; the 2024 analysis took every adult undergoing ablation in the window it covered. The follow-up differs by a factor of two, and the outcome definitions differ as well: one counted recurrence, the other counted a composite of three downstream interventions that a clinician chooses. Body mass index is doing work of its own here: it is the variable the newer cohort selected on, and the one every [pooled weight-loss estimate](https://thisglp.com/research/glp1-weight-loss-pooled-average) is built from. Either study could be right about its own population without contradicting the other, which is a more uncomfortable finding than a straightforward disagreement would be, because it means neither result generalizes cleanly to the person reading it. This shape recurs across the literature on these drugs, and we have written about it before where two meta-analyses drew [opposite conclusions from the same six trials](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials) and where studies of blood-vessel function [returned two answers](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function). The pattern is not fraud and it is rarely even error. It is what happens when a large observational database is asked a question the underlying data was not collected to answer. ## A larger comparison, and a different drug wins A network meta-analysis of 2,171,267 patients across four randomized trials and 21 cohort studies asked a related but separate question. Not whether a GLP-1 drug helps someone who already has atrial fibrillation, but whether it prevents the condition from developing at all, compared against two other diabetes drug classes [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation#ref-3). Against DPP-4 inhibitors, the standard near-neutral comparator in this literature, GLP-1 drugs showed a risk ratio of 0.93 with a confidence interval of 0.84 to 1.03. That interval crosses 1, so the honest reading is no detectable difference. SGLT-2 inhibitors separated from both, beating GLP-1 drugs at 0.86 and DPP-4 inhibitors at 0.80. For recurrence specifically — the same question the two ablation cohorts above were asking — no class separated from any other. The full comparison, including why the evidence grade matters more than the headcount, is in [the network meta-analysis writeup](https://thisglp.com/research/atrial-fibrillation-the-other-drug-won). ## What a buyer should take from it Nothing on this page is a reason to start or stop a prescription, and nobody should be buying a GLP-1 drug in order to treat an arrhythmia. What it is useful for is calibration. If a seller's page ever cites a cardiac benefit as a reason to buy, the honest version of that claim carries the population it was measured in and the length of the follow-up. Almost none of them do — an absence we have counted across the market in [what sellers do not publish](https://thisglp.com/research/what-glp1-sellers-do-not-publish). The practical question a buyer can actually act on is a duller one: who is writing the prescription, what they know about your heart, and whether the service you are paying makes that person reachable. Those are the questions worth taking to an intake, and we keep a list of them in [questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do GLP-1 drugs help atrial fibrillation? The evidence disagrees with itself. Two ablation-recurrence cohorts on the same database found a hazard ratio of 0.82 and 1.04. A separate 2,171,267-patient comparison found no significant advantage over a near-neutral drug class (risk ratio 0.93) at preventing new-onset atrial fibrillation, while SGLT-2 inhibitors did better. Why do the two ablation studies disagree? They studied different people for different lengths of time. The 2026 cohort required a body mass index above 30 and ran a median of two years; the 2024 cohort took all adults having an ablation and ran twelve months, counting a composite of cardioversion, a new antiarrhythmic drug or a repeat procedure. Which drug class did best for preventing atrial fibrillation? SGLT-2 inhibitors, in the largest of the three studies here — a risk ratio of 0.86 against GLP-1 drugs and 0.80 against DPP-4 inhibitors. Should this change what I buy? No. None of these studies was designed to guide a purchase, and no telehealth seller is prescribing for an arrhythmia. It is useful mainly as a check on any cardiac benefit a marketing page claims without naming its population or follow-up. ## Sources 1. \[1\] Venier S, et al. (2026). Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis Circulation: Arrhythmia and Electrophysiology. [PMID 41446932](https://pubmed.ncbi.nlm.nih.gov/41446932/) 2. \[2\] Satti DI, et al. (2024). Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation JACC: Clinical Electrophysiology. [PMID 38795099](https://pubmed.ncbi.nlm.nih.gov/38795099/) 3. \[3\] Ye X, Wu Q, Hou L, Hou X, Yang Y, Yang C, Huang M, Wang S (2026). Network and Pairwise Meta-Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus Diabetes/Metabolism Research and Reviews. [PMID 42455922](https://pubmed.ncbi.nlm.nih.gov/42455922/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)